A humanized UGT1 mouse model expressing the UGT1A1*28 allele for assessing drug clearance by UGT1A1-dependent glucuronidation

Drug Metabolism and Disposition

Volumn 38, Issue 5, 2010, Pages 879-886

  Cai, Hongliang ^a   Nguyen, Nghia ^b   Peterkin, Vincent ^a   Yang, Young Sun ^a   Hotz, Kathy ^a   La Placa, Deirdre Beaton ^b   Chen, Shujuan ^b   Tukey, Robert H ^b   Stevens, Jeffrey C ^a  

^a PFIZER INC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; EZETIMIBE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A3; GLUCURONOSYLTRANSFERASE 1A4; GLUCURONOSYLTRANSFERASE 1A6; GLUCURONOSYLTRANSFERASE 1A9; GLUCURONOSYLTRANSFERASE 2B7; NALOXONE; PHENOBARBITAL;

ALLELE; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EXPOSURE; GENOTYPE; GLUCURONIDATION; IN VIVO STUDY; LIVER MICROSOME; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; WILD TYPE;

ALLELES; ANIMALS; ANTICHOLESTEREMIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; AZETIDINES; BIOCATALYSIS; CAMPTOTHECIN; DIMETHYL SULFOXIDE; ENZYME INDUCTION; GENE EXPRESSION; GLUCURONIC ACID; GLUCURONOSYLTRANSFERASE; HUMANS; KINETICS; LIVER; MALE; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MICROSOMES, LIVER; MODELS, ANIMAL; NALOXONE; PHARMACEUTICAL PREPARATIONS; PHENOBARBITAL;

ANIMALIA; MUS;

EID: 77950921374     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.109.030130     Document Type: Article

References (41)

1. Ando Y, Fujita K, Sasaki Y, and Hasegawa Y (2007) UGT1AI*6 and UGT1A1*27 for individualized irinotecan chemotherapy. Curr Opin Mol Ther 9:258-262. (Pubitemid 46944317)
2. Argikar UA, Senekeo-Effenberger K, Larson EE, Tukey RH, and Remmel RP (2009) Studies on induction of lamotrigine metabolism in transgenic UGT1 mice. Xenobiotica 39:826-835.
3. Beaumont K and Smith DA (2009) Does human pharmacokinetic prediction add significant value to compound selection in drug discovery research? Curr Opin Drug Discov Devel 12:61-71.
4. Bosma PJ (2003) Inherited disorders of bilirubin metabolism. J Hepatol 38:107-117.
5. Caldwell GW, Masucci JA, Yan Z, and Hageman W (2004) Allometric scaling of pharmacokinetic parameters in drug discovery: can human CL, Vss and t1/2 be predicted from in-vivo rat data? Eur J Drug Metab Pharmacokinet 29:133-143. (Pubitemid 38828626)
6. Chen S, Beaton D, Nguyen N, Senekeo-Effenberger K, Brace-Sinnokrak E, Argikar U, Remmel RP, Trottier J, Barbier O, Ritter JK, et al. (2005) Tissue-specific, inducible, and hormonal control of the human UDP-glucuronosyltransferase-1 (UGT1) locus. J Biol Chem 280:37547-37557.
7. Cheung C and Gonzalez FJ (2008) Humanized mouse lines and their application for prediction of human drug metabolism and toxicological risk assessment. J Pharmacol Exp Ther 327: 288-299.
8. Chu XY, Kato Y, Niinuma K, Sudo KI, Hakusui H, and Sugiyama Y (1997) Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats. J Pharmacol Exp Ther 281:304-314. (Pubitemid 27203082)
9. Coffman BL, King CD, Rios GR, and Tephly TR (1998) The glucuronidation of opioids, other xenobiotics, and androgens by human UGT2B7Y(268) and UGT2B7H(268). Drug Metab Dispos 26:73-77. (Pubitemid 28071328)
10. Court MH (2005) Isoform-selective probe substrates for in vitro studies of human UDP-glucuronosyltransferases. Methods Enzymol 400:104-116.
11. De Buck SS, Sinha VK, Fenu LA, Nijsen MJ, Mackie CE, and Gilissen RA (2007) Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs. Drug Metab Dispos 35:1766-1780.
12. Ethell BT, Beaumont K, Rance DJ, and Burchell B (2001) Use of cloned and expressed human UDP-glucuronosyltransferases for the assessment of human drug conjugation and identification of potential drug interactions. Drug Metab Dispos 29:48-53. (Pubitemid 32041679)
13. Fang JL and Lazarus P (2004) Correlation between the UDP- glucuronosyltransferase (UGT1A1) TATAA box polymorphism and carcinogen detoxification phenotype: significantly decreased glucuronidating activity against benzo(a)pyrene-7,8-dihydrodiol(-) in liver microsomes from subjects with the UGT1A1*28 variant. Cancer Epidemiol Biomarkers Prev 13:102-109.
14. Fujiwara R, Nakajima M, Yamanaka H, Katoh M, and Yokoi T (2007) Interactions between human UGT1A1, UGT1A4, and UGT1A6 affect their enzymatic activities. Drug Metab Dispos 35:1781-1787.
15. Gagné JF, Montminy V, Belanger P, Journault K, Gaucher G, and Guillemette C (2002) Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38). Mol Pharmacol 62:608-617.
16. Ghosal A, Hapangama N, Yuan Y, Achanfuo-Yeboah J, Iannucci R, Chowdhury S, Alton K, Patrick JE, and Zbaida S (2004) Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of ezetimibe (Zetia). Drug Metab Dispos 32:314-320. (Pubitemid 38263889)
17. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals, 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington DC.
18. Ishii Y, Iwanaga M, Nishimura Y, Takeda S, Ikushiro S, Nagata K, Yamazoe Y, Mackenzie PI, and Yamada H (2007) Protein-protein interactions between rat hepatic cytochromes P450 (P450s) and UDP-glucuronosyltransferases (UGTs): evidence for the functionally active UGT in P450-UGT complex. Drug Metab Pharmacokinet 22:367-376.
19. Iyer L, Das S, Janisch L, Wen M, Ramírez J, Karrison T, Fleming GF, Vokes EE, Schilsky RL, and Ratain MJ (2002) UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J 2:43-47.
20. Iyer L, Hall D, Das S, Mortell MA, Ramírez J, Kim S, Di Rienzo A, and Ratain MJ (1999) Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism. Clin Pharmacol Ther 65:576-582.
21. Iyer L, King CD, Whitington PF, Green MD, Roy SK, Tephly TR, Coffman BL, and Ratain MJ (1998) Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 101:847-854.
22. Kilford PJ, Stringer R, Sohal B, Houston JB, and Galetin A (2009) Prediction of drug clearance by glucuronidation from in vitro data: use of combined cytochrome P450 and UDP-glucuronosyltransferase cofactors in alamethicin-activated human liver microsomes. Drug Metab Dispos 37:82-89.
23. Lin JH (2008) Applications and limitations of genetically modified mouse models in drug discovery and development. Curr Drug Metab 9:419-438.
24. Miners JO, Knights KM, Houston JB, and Mackenzie PI (2006) In vitro-in vivo correlation for drugs and other compounds eliminated by glucuronidation in humans: pitfalls and promises. Biochem Pharmacol 71:1531-1539.
25. Miners JO, Mackenzie PI, and Knights KM (2010) The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro-in vivo extrapolation of drug clearance and drug-drug interaction potential. Drug Metab Rev 42:189-201.
26. Miners JO, McKinnon RA, and Mackenzie PI (2002) Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance. Toxicology 181-182:453-456.
27. Miners JO, Smith PA, Sorich MJ, McKinnon RA, and Mackenzie PI (2004) Predicting human drug glucuronidation parameters: application of in vitro and in silico modeling approaches. Annu Rev Pharmacol Toxicol 44:1-25.
28. Nagar S and Blanchard RL (2006) Pharmacogenetics of uridine diphosphoglucuronosyltransferase (UGT) 1A family members and its role in patient response to irinotecan. Drug Metab Rev 38:393-409.
29. Nguyen N, Bonzo JA, Chen S, Chouinard S, Kelner MJ, Hardiman G, Bélanger A, and Tukey RH (2008) Disruption of the ugt1 locus in mice resembles human Crigler-Najjar type I disease. J Biol Chem 283:7901-7911.
30. O'Dwyer PJ and Catalano RB (2006) Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy. J Clin Oncol 24:4534-4538.
31. Onoue M and Inui K (2008) [Role of UGT1A1*28 and UGT1A1*6 for irinotecan-induced adverse drug reaction]. Gan To Kagaku Ryoho 35:1080-1085.
32. Operaña TN and Tukey RH (2007) Oligomerization of the UDP-glucuronosyltransferase 1A proteins: homo- and heterodimerization analysis by fluorescence resonance energy transfer and co-immunoprecipitation. J Biol Chem 282:4821-4829.
33. Peterkin VC, Bauman JN, Goosen TC, Menning L, Man MZ, Paulauskis JD, Williams JA, and Myrand SP (2007) Limited influence of UGT1A1*28 and no effect of UGT2B7*2 polymorphisms on UGT1A1 or UGT2B7 activities and protein expression in human liver microsomes. Br J Clin Pharmacol 64:458-468.
34. Rowland A, Knights KM, Mackenzie PI, and Miners JO (2008) The "albumin effect" and drug glucuronidation: bovine serum albumin and fatty acid-free human serum albumin enhance the glucuronidation of UDP-glucuronosyltransferase (UGT) 1A9 substrates but not UGT1A1 and UGT1A6 activities. Drug Metab Dispos 36:1056-1062.
35. Soars MG, Ring BJ, and Wrighton SA (2003) The effect of incubation conditions on the enzyme kinetics of UDP-glucuronosyltransferases. Drug Metab Dispos 31:762-767.
36. Strassburg CP, Kneip S, Topp J, Obermayer-Straub P, Barut A, Tukey RH, and Manns MP (2000) Polymorphic gene regulation and interindividual variation of UDP-glucuronosyltransferase activity in human small intestine. J Biol Chem 275:36164-36171.
37. Takeda S, Ishii Y, Mackenzie PI, Nagata K, Yamazoe Y, Oguri K, and Yamada H (2005) Modulation of UDP-glucuronosyltransferase 2B7 function by cytochrome P450s in vitro: differential effects of CYP1A2, CYP2C9 and CYP3A4. Biol Pharm Bull 28:2026-2027.
38. Tukey RH and Strassburg CP (2000) Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 40:581-616.
39. Tukey RH, Strassburg CP, and Mackenzie PI (2002) Pharmacogenomics of human UDP-glucuronosyltransferases and irinotecan toxicity. Mol Pharmacol 62:446-450.
40. Udomuksorn W, Elliot DJ, Lewis BC, Mackenzie PI, Yoovathaworn K, and Miners JO (2007) Influence of mutations associated with Gilbert and Crigler-Najjar type II syndromes on the glucuronidation kinetics of bilirubin and other UDP-glucuronosyltransferase 1A substrates. Pharmacogenet Genomics 17:1017-1029.
41. Zhang D, Zhang D, Cui D, Gambardella J, Ma L, Barros A, Wang L, Fu Y, Rahematpura S, Nielsen J, et al. (2007) Characterization of the UDP glucuronosyltransferase activity of human liver microsomes genotyped for the UGT1A1*28 polymorphism. Drug Metab Dispos 35: 2270-2280.